Nazione: Irlanda
Lingua: inglese
Fonte: HPRA (Health Products Regulatory Authority)
GADOBENATE DIMEGLUMINE
Bracco SPA
0.5M
Solution for Injection
1998-04-03
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT MultiHance, 0.5M solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution for injection contains: gadobenic acid 334 mg (0.5M) as the dimeglumine salt. [Gadobenate dimeglumine 529 mg = gadobenic acid 334 mg + meglumine 195 mg]. For list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection Clear aqueous solution filled into colourless glass vials. Osmolality at 37°C: 1.97 osmol/kg Viscosity at 37°C: 5.3 mPa.s 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medicinal product is for diagnostic use only. MultiHance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) indicated for : • MRI of the liver for the detection of focal liver lesions in patients with known or suspected primary liver cancer (eg. hepatocellular carcinoma) or metastatic disease. • MRI of the brain and spine where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI. • Contrast-enhanced MR- angiography where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease in patients with suspected or known vascular disease of the abdominal or peripheral arteries. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION MRI of the liver: the recommended dose of MultiHance injection in adult patients is 0.05 mmol/kg body weight. This corresponds to 0.1 mL/kg of the 0.5 M solution. MRI of the brain and spine : the recommended dose of MultiHance injection in adult and in paediatric patients greater than 2 years of age is 0.1 mmol/kg body weight. This corresponds to 0.2 mL/kg of the 0.5 M solution. MRA: the recommended dose of MultiHance injection in a Leggi il documento completo